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Okayama University research :  Simplified boron compound may treat brain tumours 
  
(Okayama, 16 September) Effective and targeted uptake among malignant cells 
demonstrates the promise of a simplified boron compound for neutron radiation therapy, 
report researchers at Okayama University and Kinki University. 
 
“Glioblastoma multiforme is the most common malignant central nervous system primary 
tumour that has been incurable for decades,” explain Hideki Matsui and colleagues at 
Okayama University Graduate School of Medicine and Kinki University in their recent report. 
Treatment with ‘boron neutron capture therapy’ (BNCT) has been found to double the 
duration of patient survival, but finding effective compounds for it has been challenging. 
Now Michiue and colleagues have demonstrated - both in cell lines and mice - a readily 
made boron compound that targets and penetrates tumour cells for effective BNCT [1].  
 
The compound BSH is high in boron content and has the advantage of accumulating 
primarily in tumour tissue rather than healthy tissue. However BSH does not penetrate 
inside the tumour cells limiting the therapeutic effects of BNCT using it. 
 
Previously Michiue and a collaboration of researchers in Japan demonstrated they could 
enhance cell penetration by fusing BSH with a large peptide comprising up to 11 amino acid 
‘arginine’ groups [2]. However with the large added peptide it was difficult both to produce 
the compound and track its effects in the body. 
 
Studies of protein transcription aided by a smaller version of the peptide suggested that a 
compromise in size may allow effective BSH cell penetration without the need for 
prohibitively complicated synthesis techniques. [3]. The latest results from Michiue and 
colleagues have now shown that while peptides with just one or two arginine groups were 
ineffective, three arginine groups were enough to improve cell uptake.  
 
The BSH fused with a peptide of three arginine groups was simpler to produce and they 
could also track the drug in the body using positron emission tomography. They conclude, 
“In our present study, we discovered that BSH-3R overcame many obstacles to develop a 
BSH-peptide suitable for future clinical use.” 
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Background 
Boron neutron capture therapy 
One of the challenges with treating glioblastoma multiforme is removing all cancer cells 
without causing damage to the brain. The destruction of nearby healthy cells is a significant 
side effect for traditional radiation therapy.  
 
BCNT has attracted particular interest because the radiation caused is highly localised.  
When boron is delivered to malignant cancer cells, irradiation with low-energy thermal 
neutrons then triggers boron fission into a high energy alpha particle and lithium atom. 
While lethal to cells in their direct path the high-energy alpha particle and lithium atom 
produced cannot travel further than roughly a cell length before their energy is absorbed 
leaving nearby healthy cells intact.  
 
BNCT has already been used clinically for treating brain tumours, malignant melanoma, 
head and neck cancers, and hepatoma. Hospital sources for low-thermal-energy neutrons to 
trigger the fission are in continued development. However clinical use so far has highlighted 
shortcomings in the boron delivery drugs currently available. 
 
Boron delivery drugs 
Previous clinically used drugs for BNCT include an essential amino acid analog p-borono-
Lphenylalanine (BPA) and disodium mercaptoundecahydrododecaborate  ([B12HnSH]2-2Na+, 
BSH). BPA readily delivers high boron content to cells but it does not target malignant cells 
alone and is not taken up by slowly proliferating malignant cells.  
 
In contrast accumulation of BSH is greatly enhanced in tumour regions but it is present 
between the cells making it less effective for BNCT. Simulations in previous work have 
highlighted the limitations of BNCT from outside the cell. 
 
Arginine 
Arginine is a type of amino acid. Previous work has shown that with an 11-arginine-strong 
peptide the cancer killing effect of the BSH compound was greater than with a dose 100 
times stronger of BSH without the added peptide. However it is difficult to synthesise BSH 
with the 11-arginine peptide and it cannot be readily tracked to monitor its effects in the 
body. The results of this latest work resolve some of the practical issues around using 
arginine groups to improve BSH cell penetration for cancer treatment using BNCT. 
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Chemical structures of the readily synthesised BSH fused with comparatively short ‘nR’ 
peptides, where R is the arginine group and n is the number of arginine groups.  When fused 
with 3R the BSH penetrates the cell for effective BNCT.  The chemical is additionally readily 
fused with a fluorescent moiety, Tmr (a), and DOTA for positron emission tomography scans 
(b) to track the drug in the body. 
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Okayama University Medical Research Updates （OU-MRU） 
Vol.1：Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells 
from blood samples for genetic testing 
Vol.2：Ensuring a cool recovery from cardiac arrest 
Vol.3：Organ regeneration research leaps forward 
Vol.4：Cardiac mechanosensitive integrator 
Vol.5：Cell injections get to the heart of congenital defects 
Vol.6：Fourth key molecule identified in bone development 
Vol.7：Anticancer virus solution provides an alternative to surgery 
Vol.8：Light-responsive dye stimulates sight in genetically blind patients 
Vol.9：Diabetes drug helps towards immunity against cancer 
Vol.10：Enzyme-inhibitors treat drug-resistant epilepsy 
Vol.11：Compound-protein combination shows promise for arthritis treatment 
Vol.12：Molecular features of the circadian clock system in fruit flies 















About Okayama University 
Okayama University is one of the largest 
comprehensive universities in Japan with 
roots going back to the Medical Training 
Place sponsored by the Lord of Okayama 
and established in 1870. Now with 1,300 
faculty and 14,000 students, the University 
offers courses in specialties ranging from 
medicine and pharmacy to humanities 
a n d  p h y s i c a l  s c i e n c e s .  O k a y a m a 
University is located in the heart of Japan 
approximately 3 hours west of Tokyo by 
Shinkansen. 
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